Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.
Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback